Skip to main content
Top
Published in: Neurological Sciences 7/2020

Open Access 01-07-2020 | Obsessive-Compulsive Disorder | Brief Communication

Pharmacotherapy for tics in adult patients with Tourette syndrome and other tic disorders

Authors: James Badenoch, Andrea E. Cavanna

Published in: Neurological Sciences | Issue 7/2020

Login to get access

Abstract

Background

Tourette syndrome (TS) and persistent motor/vocal tic disorders are neurodevelopmental conditions characterised by the chronic presence of motor and/or vocal tics. Patients with TS often present with co-morbid disorders, especially attention-deficit and hyperactivity disorder (which tends to improve after childhood), and obsessive-compulsive disorder (which can persist in adulthood). We set out to explore pharmacotherapy for tics in adult patients with TS and persistent motor/vocal tic disorders, as well as its relationship with the presence of co-morbid conditions.

Methods

We retrospectively reviewed the clinical characteristics and pharmacotherapy of 192 adult patients with TS (n = 187), persistent motor tic disorder (n = 3) and persistent vocal tic disorder (n = 2) attending a specialist clinic in the UK.

Results

Anti-dopaminergic medications (n = 65) and alpha-2-agonists (n = 50) were the most commonly prescribed pharmacotherapy for tic management. A sub-group analysis revealed that co-morbid obsessive-compulsive disorder and sub-threshold obsessive-compulsive behaviours were significantly more common in patients treated with anti-dopaminergic medications than patients taking alpha-2-agonists (p = 0.013 and p = 0.047, respectively).

Conclusions

The use of pharmacotherapy options for tic management observed at a specialist clinic for adults with TS reflects guideline recommendations. We found that the presence of co-morbid obsessive-compulsive disorder/behaviours correlates with the choice of anti-dopaminergic medications over alpha-2-agonists, in line with available evidence on the efficacy of anti-dopaminergic medications for the treatment of specific tic–related behavioural symptoms.
Literature
1.
go back to reference Cavanna AE (2018) Gilles de la Tourette syndrome as a paradigmatic neuropsychiatric disorder. CNS Spectr 23:213–218CrossRefPubMed Cavanna AE (2018) Gilles de la Tourette syndrome as a paradigmatic neuropsychiatric disorder. CNS Spectr 23:213–218CrossRefPubMed
2.
go back to reference Pringsheim T, Okun MS, Muller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J (2019) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92:896–906CrossRefPubMedPubMedCentral Pringsheim T, Okun MS, Muller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J (2019) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92:896–906CrossRefPubMedPubMedCentral
3.
go back to reference Robertson MM, Eapen V (1996) The National Hospital Interview Schedule for the assessment of Gilles de la Tourette syndrome. Int J Methods Psychiatr Res 6:203–226CrossRef Robertson MM, Eapen V (1996) The National Hospital Interview Schedule for the assessment of Gilles de la Tourette syndrome. Int J Methods Psychiatr Res 6:203–226CrossRef
4.
go back to reference Robertson MM, Banerjee S, Kurlan R, Cohen DJ, Leckman JF, McMahon W, Pauls DL, Sandor P, van de Wetering BJ (1999) The Tourette syndrome Diagnostic Confidence Index: development and clinical associations. Neurology 53:2108–2112CrossRefPubMed Robertson MM, Banerjee S, Kurlan R, Cohen DJ, Leckman JF, McMahon W, Pauls DL, Sandor P, van de Wetering BJ (1999) The Tourette syndrome Diagnostic Confidence Index: development and clinical associations. Neurology 53:2108–2112CrossRefPubMed
5.
go back to reference Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ (1989) The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566–573CrossRefPubMed Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ (1989) The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566–573CrossRefPubMed
6.
go back to reference McGuire JF, Piacentini J, Storch EA, Murphy TK, Ricketts EJ, Woods DW, Walkup JW, Peterson AL, Wilhelm S, Lewin AB, McCracken JT, Leckman JF, Scahill L (2018) A multicenter examination and strategic revisions of the Yale Global Tic Severity Scale. Neurology 90:e1711–e1719CrossRefPubMedPubMedCentral McGuire JF, Piacentini J, Storch EA, Murphy TK, Ricketts EJ, Woods DW, Walkup JW, Peterson AL, Wilhelm S, Lewin AB, McCracken JT, Leckman JF, Scahill L (2018) A multicenter examination and strategic revisions of the Yale Global Tic Severity Scale. Neurology 90:e1711–e1719CrossRefPubMedPubMedCentral
7.
go back to reference Cothros N, Martino D, McMorris C, Stewart D, Tehrani A, Pringsheim T (2019) Prescriptions for alpha agonists and antipsychotics in children and youth with tic disorders: a pharmacoepidemiologic study. Tremor Other Hyperkinet Mov (N Y) 9 Cothros N, Martino D, McMorris C, Stewart D, Tehrani A, Pringsheim T (2019) Prescriptions for alpha agonists and antipsychotics in children and youth with tic disorders: a pharmacoepidemiologic study. Tremor Other Hyperkinet Mov (N Y) 9
8.
go back to reference Cavanna AE, Selvini C, Termine C, Balottin U, Eddy CM (2012) Tolerability profile of clonidine in the treatment of adults with Tourette syndrome. Clin Neuropharmacol 35:269–272CrossRefPubMed Cavanna AE, Selvini C, Termine C, Balottin U, Eddy CM (2012) Tolerability profile of clonidine in the treatment of adults with Tourette syndrome. Clin Neuropharmacol 35:269–272CrossRefPubMed
9.
go back to reference Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, Muller-Vahl K, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M (2019) Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92:907–915CrossRefPubMedPubMedCentral Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, Muller-Vahl K, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M (2019) Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92:907–915CrossRefPubMedPubMedCentral
10.
go back to reference Gerasch S, Kanaan AS, Jakubovski E, Müller-Vahl KR (2016) Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Front Neurosci 10:416CrossRefPubMedPubMedCentral Gerasch S, Kanaan AS, Jakubovski E, Müller-Vahl KR (2016) Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Front Neurosci 10:416CrossRefPubMedPubMedCentral
Metadata
Title
Pharmacotherapy for tics in adult patients with Tourette syndrome and other tic disorders
Authors
James Badenoch
Andrea E. Cavanna
Publication date
01-07-2020
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 7/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04327-3

Other articles of this Issue 7/2020

Neurological Sciences 7/2020 Go to the issue